Neeva Brings Responsible, Citation-Backed AI Powered Search to Europe
13.2.2023 14:00:00 EET | Business Wire | Press release
Advert and tracker-free search engine Neeva has today launched NeevaAI in Europe, which harnesses the power of artificial intelligence (AI) to deliver an experience that combines the best of large language models such as ChatGPT with the authority and timeliness of search.
Following a successful beta launch in the US in December 2022, NeevaAI is available to Free Basic and Premium users across the world from today. NeevaAI will be launching its English Language version in the UK and Canada, as well as local language versions in Germany, France and Spain.
NeevaAI provides a synthesised single answer with linked sources pulled together from the most relevant sites for a query, allowing users to determine the authenticity and reliability of the cited sources. The feature offers current information by crawling hundreds of millions of pages a day and serving from its independent index of billions of pages. By combining AI with Neeva's in-house search stack that eschews ads and advertisers, results are fast, timely, bias-free and relevant.
Real-time summaries backed by sources
Unlike other AI search offerings, NeevaAI offers current information to the user by interrogating a page, understanding its contents and incoming links to determine whether the page is useful and authoritative and cite the information source. NeevaAI does this in real time as the web changes, which is vital in our fast paced world.
In a feature unique to Neeva, NeevaAI also provides citation cards, in which a search query returns a visual search result with machine learning summaries from all the top results and swipeable cards highlighting authoritative information about the researched topic. The cards also suggest important research questions for the searcher.
Neeva Founder and CEO, Sridhar Ramaswamy comments: “AI is already beginning to make search one of the first and most clearly disrupted industries. NeevaAI leverages in-house LLMs and refined training models with its full system search stack to bring authentic real time AI search to the everyones. Our goal has been to responsibly integrate AI and provide authoritative answers that you can trust.”
Support for publishers in a post-ChatGPT world
Publishers and content creators stand to be greatly impacted by certain AI search models. AI will fundamentally shift individuals’ relationship to finding and consuming information. For publishers, this should be canary in the coal mine, and failing to adapt to this new reality could prove catastrophic for their businesses.
Nowhere is the threat more immediate than in search. As search engines become answer engines, publisher content will get sucked into the AI bots and served back to users without attribution or links. Without links embedded in the AI answer, users won’t find their way to a publisher’s website, effectively choking off the referral traffic pipeline. Significant drops in referral traffic will lead to material impacts on ad revenue especially at a time when most publishers are fighting just to stay afloat. To make matters worse, that same content will also be used to further train large language models (LLMs) exacerbating the publisher’s dilemma.
Neeva is committed to helping publishers leverage AI and LLMs to re-take ownership of the relationships with their users. Neeva is working to help publishers integrate fluent AI search natively in their websites allowing users to discover and consume content seamlessly. Moreover, to support publishers, whose referral traffic is now at greater risk from AI answer bots, Neeva has committed 20% of its topline revenue to content creator and publisher partners when their content is used to directly answer a Neeva customer’s query.
Since launching in the US in 2021, and Europe in late 2022, Neeva has amassed nearly 2 million users. It has built one of the largest independent search stacks crawling hundreds of millions of pages a day and an index of billions. By combining AI with Neeva’s in-house search stack, NeevaAI’s results are lightning fast, timely, and relevant.
ENDS
About Neeva
Neeva is the world’s first ads-free, private subscription search engine powered by AI. Neeva focuses entirely on the consumer, delivering only real, high quality, trustworthy results. Neeva is leading a new AI frontier by leveraging in-house LLMs and refined training models with our full system search stack to bring authentic real-time AI search to everyone. Neeva blocks third-party website trackers, and will never sell or share customer data with anyone, especially advertisers. Neeva also makes it easy to search within personal email accounts, calendars, and cloud storage platforms surfacing the most important information from the same familiar search box. The company was founded by former executives from Google and YouTube. Learn more and start searching today at neeva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230213005065/en/
Contact information
Contact details
press@neeva.co
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
